Literature DB >> 12959074

Development of a candidate polyvalent live vaccine against human immunodeficiency, hepatitis B, and orthopox viruses.

S N Shchelkunov1, A E Nesterov, I A Ryazankin, G M Ignat'ev, L S Sandakhchiev.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12959074     DOI： 10.1023/a:1024476626759

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


× No keyword cloud information.
  8 in total

1.  Public-private partnerships for health: their main targets, their diversity, and their future directions.

Authors:  R Widdus
Journal:  Bull World Health Organ       Date:  2001-10-24       Impact factor: 9.408

2.  [Design of four-helix protein--a possible vaccine against human immunodeficiency virus (HIV-1)].

Authors:  A M Eroshkin; P A Zhilkin; V V Shamin
Journal:  Mol Biol (Mosk)       Date:  1993 May-Jun

Review 3.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype.

Authors:  R M Buller; G L Smith; K Cremer; A L Notkins; B Moss
Journal:  Nature       Date:  1985 Oct 31-Nov 6       Impact factor: 49.962

5.  DNA-mediated immunization to hepatitis B virus envelope proteins: preS antigen secretion enhances the humoral response.

Authors:  R Prange; M Werr
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

6.  Design of four-helix bundle protein as a candidate for HIV vaccine.

Authors:  A M Eroshkin; E A Karginova; I P Gileva; A S Lomakin; L R Lebedev; T P Kamyinina; A V Pereboev; G M Ignat'ev
Journal:  Protein Eng       Date:  1995-02

7.  Modeling potential responses to smallpox as a bioterrorist weapon.

Authors:  M I Meltzer; I Damon; J W LeDuc; J D Millar
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728
  8 in total
  3 in total

1.  Selection of a peptide mimicking neutralization epitope of hepatitis E virus with phage peptide display technology.

Authors:  Ying Gu; Jun Zhang; Ying-Bing Wang; Shao-Wei Li; Hai-Jie Yang; Wen-Xin Luo; Ning-Shao Xia
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

2.  Effect of the Route of Administration of the Vaccinia Virus Strain LIVP to Mice on Its Virulence and Immunogenicity.

Authors:  Sergei N Shchelkunov; Stanislav N Yakubitskiy; Alexander A Sergeev; Alexei S Kabanov; Tatiana V Bauer; Leonid E Bulychev; Stepan A Pyankov
Journal:  Viruses       Date:  2020-07-24       Impact factor: 5.048

3.  Enhancing the Protective Immune Response to Administration of a LIVP-GFP Live Attenuated Vaccinia Virus to Mice.

Authors:  Sergei N Shchelkunov; Stanislav N Yakubitskiy; Kseniya A Titova; Stepan A Pyankov; Alexander A Sergeev
Journal:  Pathogens       Date:  2021-03-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.